난치 각막상피질환 환자에서 5% 혈청알부민 점안액의 효과: 임상증례 및 문헌고찰
The Effect of 5% Serum Albumin on Intractable Corneal Epithelial Keratitis: a Case Series and Literature Review
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
목적: 저자들은 5안의 다양한 난치 각막상피질환에서 5% 혈청알부민 점안액의 치료 효과를 경험하였기에 문헌고찰과 함께 보고하고자 한다. 대상과 방법: 안과 외래에서 난치 각막상피질환으로 치료받던 환자 중 5% 혈청알부민 점안액의 치료 효과를 경험한 5안의 의무기록을 후향적으로 분석하였다. 환자들은 모두 다른 치료제, 즉 무방부제 인공누액이나 자가혈청점안액을 이미 사용하고 있었다. 치료 시작 전의 각막상피결손의 크기 및 상피결손이 완전히 닫힐 때까지 걸린 시간 등을 관찰하였다. 결과: 5명의 환자의 각막 병변에 관한 평균 6개월간의 치료 기간 동안의 경과관찰을 하였다. 상피병변은 혈청알부민의 치료 시작 초기부터 효과를 보였고, 경과관찰 기간 동안 유지되었다. 치료 시작부터 상피결손이 닫힐 때까지 걸린 평균 시간은 21일이었다. 결론: 5% 혈청알부민 점안액은 난치 각막상피질환에 우수한, 안정된 치료 효과를 보일 가능성이 있다.
Abstract
Purpose: We report five cases of intractable epithelial keratitis in which 5% serum albumin showed significant effects as a topical treatment when compared with other previous conservative treatments based on a literature review. Methods: This was a retrospective observational case series of five patients with intractable corneal epithelial keratitis who used serum albumin as a topical treatment. All patients had already been using other conservative treatments such as non-preserved artificial tears and autologous serum eye drops. The size of the epithelial defect and the time taken for closure of the epithelial defect were observed. Results: The study involved five patients with intractable corneal epithelial disease with a mean follow-up time of 6 months. The epithelial lesions improved with the use of 5% serum albumin from the beginning of treatment and lasted throughout the follow- up period. The mean time to complete epithelial closure using 5% serum albumin eye drops was 21 days. Conclusions: Treatment with 5% serum albumin eye drops may have a significant and stable effect in the treatment of intractable corneal epithelial disease.
참고문헌 (36)
- Tsubota K, "Serum application for the treatment of ocular surface disorders", Int Ophthalmol Clin, 40, pp.113~122 (2000)[DOI]
- Fukuda M, "Dry eye and closed eye tears", Cornea, 19(3 Suppl), pp.S44~S48 (2000)[DOI]
- Geerling G, "Autologous serum and alternative blood products for the treatment of ocular surface disorders", Ophthalmologe, 105, pp.623~631 (2008)[DOI]
- Seki JT, "Human albumin eye drops as a therapeutic option for the management of keratoconjunctivitis sicca secondary to chronic graft-versus-host disease after stem-cell allografting", Curr Oncol, 22, pp.e357~e363 (2015)[DOI]
- del Castillo JM, "Treatment of recurrent corneal erosions using autologous serum", Cornea, 21, pp.781~783 (2002)[DOI]
- Ohashi Y, "Presence of epidermal growth factor in human tears", Invest Ophthalmol Vis Sci, 30, pp.1879~1882 (1989)
- Ubels JL, "Retinol secretion by the lacrimal gland", Invest Ophthalmol Vis Sci, 27, pp.1261~1268 (1986)
- Fox RI, "Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca", Arthritis Rheum, 27, pp.459~461 (1984)[DOI]
- Tananuvat N, "Controlled study of the use of autologous serum in dry eye patients", Cornea, 20, pp.802~806 (2001)[DOI]
- Ogawa Y, "Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graftversus-host disease", Bone Marrow Transplant, 31, pp.579~583 (2003)[DOI]
- Noble BA, "Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease", Br J Ophthalmol, 88, pp.647~652 (2004)[DOI]
- Poon AC, "Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies", Br J Ophthalmol, 85, pp.1188~1197 (2001)[DOI]
- Tsubota K, "Treatment of dry eye by autologous serum application in Sjogren's syndrome", Br J Ophthalmol, 83, pp.390~395 (1999)[DOI]
- Matsumoto Y, "Autologous serum application in the treatment of neurotrophic keratopathy", Ophthalmology, 111, pp.1115~1120 (2004)[DOI]
- Tsubota K, "Treatment of persistent corneal epithelial defect by autologous serum application", Ophthalmology, 106, pp.1984~1989 (1999)[DOI]
- 한명수, "반복성 점상 각막미란에서 자가혈청 국소점안의 치료 효과", 대한안과학회지, 45(10), pp.6~6 (2004), 대한안과학회
- 최정한, "이식편대숙주질환과 관련된 건성안 환자에서 사이클로스포린A과 제대혈청 병합치료의 효과", 대한안과학회지, 54(4), pp.587~594 (2013), 대한안과학회
- Lee GA, "Autologous serum in the management of recalcitrant dry eye syndrome", Clin Exp Ophthalmol, 36, pp.119~122 (2008)[DOI]
- Eberle J, "HIV-1 infection transmitted by serum droplets into the eye: a case report", AIDS, 14, pp.206~207 (2000)[DOI]
- Weisbach V, "HIV and hepatitis B", C infections in patients donating blood for use as autologous serum eye drops, 2007, pp.91, 1724~1725
- Ralph RA, "Clinical experience with a mobile ocular perfusion pump", Arch Ophthalmol, 93, pp.1039~1043 (1975)[DOI]
- Coyle PK, "Electrophoresis combined with immunologic identification of human tear proteins", Invest Ophthalmol Vis Sci, 30, pp.1872~1878 (1989)
- Kuizenga A, "SDS-Minigel electrophoresis of human tears. Effect of sample treatment on protein patterns", Invest Ophthalmol Vis Sci, 32, pp.381~386 (1991)
- Nicholson JP, "The role of albumin in critical illness", Br J Anaesth, 85, pp.599~610 (2000)[DOI]
- Higuchi A, "Albumin rescues ocular epithelial cells from cell death in dry eye", Curr Eye Res, 32, pp.83~88 (2007)[DOI]
- Shimmura S, "Albumin as a tear supplement in the treatment of severe dry eye", Br J Ophthalmol, 87, pp.1279~1283 (2003)[DOI]
- Cao G, "Oxygen-radical absorbance capacity assay for antioxidants", Free Radic Biol Med, 14, pp.303~311 (1993)[DOI]
- Cantin AM, "Albumin-mediated regulation of cellular glutathione and nuclear factor kappa B activation", Am J Respir Crit Care Med, 162, pp.1539~1546 (2000)[DOI]
- Zhang WJ, "Albumin selectively inhibits TNF alpha-induced expression of vascular cell adhesion molecule-1 in human aortic endothelial cells", Cardiovasc Res, 55, pp.820~829 (2002)[DOI]
- Unterlauft JD, "Albumin eye drops for treatment of ocular surface diseases", Ophthalmologe, 106, pp.932~937 (2009)[DOI]
- Schargus M, "Treatment of severe ocular surface disorders with albumin eye drops", J Ocul Pharmacol Ther, 31, pp.291~295 (2015)[DOI]
- Petrides PE, "An improved method for the purification of human insulin-like growth factors I and II", Endocrinology, 118, pp.2034~2038 (1986)[DOI]
- Kojima T, "Autologous serum eye drops for the treatment of dry eye diseases", Cornea, 27(Suppl 1), pp.S25~S30 (2008)[DOI]
- Yu FS, "Growth factors and corneal epithelial wound healing", Brain Res Bull, 81, pp.229~235 (2010)[DOI]
- Gupta A, "Transforming growth factor beta-1 and beta-2 in human tear fluid", Curr Eye Res, 15, pp.605~614 (1996)[DOI]
- Cho YK, "Comparison of autologous serum eye drops with different diluents", Curr Eye Res, 38, pp.9~17 (2013)[DOI]